Lipoprotein lipase (LPL) hydrolyzes circulating triglycerides (TGs). We previously showed that 3 0 -end haplotypes in the LPL gene influence atherosclerosis and insulin resistance. This study asked whether these LPL haplotypes influence response to lipid-lowering therapy among 829 subjects from the Post-Coronary Artery Bypass Graft trial. Lipid profiles were obtained at baseline and 4-5 years after treatment with lovastatin. Haplotypes were based on 12 SNPs. The fourth most frequent haplotype, 12-4, was associated with a decreased increment in high-density lipoprotein-cholesterol (HDL-C) following treatment. Haplotypes 12-6, 12-7 and 12-8 were each associated with increased HDL-C response to therapy, and haplotype 12-2 with decreased TG response. The most common haplotype, 12-1, was protective against graft worsening or occlusion. Haplotype 12-4 reduced HDL-C response to lovastatin, possibly consistent with our prior observations of this haplotype as predisposing to coronary artery disease. LPL may influence atherosclerosis risk through pleiotropic effects on each aspect of the metabolic syndrome.
Introduction
Lipoprotein lipase (LPL) governs the delivery of triglyceride (TG)-derived free fatty acids to adipose tissue and muscle. LPL is also expressed in vascular wall cells (monocytes, smooth muscle cells) where it may play a role in lipid uptake and foam cell formation. Given these roles, the LPL gene has been examined as a candidate gene for dyslipidemia, [1] [2] [3] [4] obesity, 4 hypertension, 5, 6 insulin resistance 1, 7, 8 and atherosclerosis. [9] [10] [11] Our work has focused on the 3 0 -end of the LPL gene, wherein haplotypes were associated with insulin resistance, atherosclerosis, obesity and multiple lipid and blood pressure traits related to the metabolic syndrome. 8, 11, 12 A haplotype consisting of 19 variants (designated haplotype spanning from intron 7 to exon 10 was associated with increased post-heparin plasma LPL activity, as well as insulin resistance, obesity and increased blood pressure. 12 As a key regulator of lipid metabolism, genetic variants in the LPL gene may influence the response to lipid-lowering drug therapy. Very few studies have examined this question. The REGRESS study found that the D9N variant in LPL attenuated the total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) response to pravastatin, but had no significant effect on angiographic progression of coronary artery lesions. 13 In our initial studies in the Post-Coronary Artery Bypass Graft Trial (Post-CABG Trial) cohort, we observed no effect of D9N, whereas the HindIII variant in LPL was associated with increased coronary graft narrowing over time, independent of the degree of lipid lowering (moderate versus aggressive) with lovastatin. 14, 15 In this study, we expand on the latter result, examining the association of LPL haplotypes with the atherosclerosis and lipid response to lovastatin therapy. Our findings indicate that LPL haplotypes are associated with graft worsening and occlusion, and high-density lipoprotein-cholesterol (HDL-C) and TG response to statin (3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor) treatment. Notably, the haplotype associated with impaired HDL-C response to statin treatment in the Post-CABG cohort is the same haplotype associated with insulin resistance, atherosclerosis and increased LPL activity in a Mexican-American cohort at risk for coronary artery disease. Also, a different haplotype, associated with protection against atherosclerosis in the Mexican Americans, was associated with protection against graft narrowing or occlusion in the Post-CABG subjects.
Results
The clinical characteristics of 891 fully phenotyped subjects are shown in Table 1 . In the Post-CABG trial, an overall 15% reduction in TC and a 26% reduction in LDL-C was observed. 15 The aggressive treatment group had significantly greater reductions in these parameters than the moderate treatment group (TC: 23 versus 7%; LDL-C: 37 versus 14%, both Po0.0001). Response in HDL-C and TGs did not differ between the two treatment groups. A wide range of lipid responses was observed. Gender or race did not influence lipid response.
We genotyped 12 single nucleotide polymorphisms (SNPs) in the LPL gene. Table 2 shows the frequency and position information of the 12 LPL variants based on genotyping in all 903 subjects. We were able to successfully genotype and assign a common haplotype to 829 of the phenotyped and genotyped subjects. Linkage disequilibrium (D 0 ) among the 12 SNPs (the HindIII variant plus 11 additional SNPs) ranged from 0.55 to 1 (average D 0 of 0.92). The haplotypes constructed based on these 12 variants are listed in Table  3 , along with their respective frequencies. These haplotypes are labeled 12-1, 12-2, 12-3, etc. to denote that they are based on a total of 12 polymorphisms, and to avoid confusion with the previously reported 19-SNP-based haplotypes. The eight most frequent haplotypes together comprise 96% of the haplotypes found in this population. The original 19-SNP-based haplotypes are also listed in Table  3 , in rows corresponding to the new 12-SNP-based haplotypes. The latter shows that the common haplotypes are shared between the largely Caucasian Post-CABG population and the Mexican-American cohort, albeit with modest differences in frequency.
Haplotype 12-1, the most common haplotype, was associated with protection against progression of atherosclerosis (covariate-adjusted odds ratio (OR) 0.69, 95% confidence interval (CI) 0.49-0.97, P ¼ 0.03); 41.4% of carriers of this haplotype experienced graft worsening compared with 48.9% of non-carriers. Furthermore, the mean proportion of grafts per subject showing progression of atherosclerosis was also significantly decreased for those carrying haplotype 12-1: 27% for haplotype 12-1 carriers compared with 32% for non-carriers of this haplotype (P ¼ 0.048). Haplotype 12-1 carriers were also protected was associated with a decreased increment in HDL-C (12-4 carriers: þ 6.8% HDL-C response versus non-carriers: þ 14.3% HDL-C response, P ¼ 0.005) ( Table 4) . Conversely, three rare haplotypes, 12-6, 12-7 and 12-8, were each associated with increased HDL-C response to therapy compared to respective non-carriers (Table 4 ). Haplotype 12-2 was associated with a smaller increment in TGs (12-2 carriers: þ 2.6% versus non-carriers: þ 11.8% change in TGs, P ¼ 0.02). The effects of LPL haplotypes on HDL-C and TG response were independent of whether subjects were in the intensive or moderate treatment group. LPL haplotypes were not associated with TC or LDL-C response to lipid-lowering therapy.
Secondary The Mexican-American Coronary Artery Disease (MACAD) study, a study of adult offspring of Mexican-American probands with coronary artery disease. 8, 11, 12 (42.0711.4 mg/dl) in carriers, versus 1.0170.25 mmol/l (39.279.6 mg/dl) in non-carriers (P ¼ 0.032). No LPL haplotype was associated with baseline levels of TC, LDL-C or TG. Given the associations of haplotypes 12-1 and 12-4 with DBP, we re-analyzed the associations of these haplotypes with the primary phenotypes of atherosclerosis progression and lipid response by including DBP as a covariate in the analyses. The associations between haplotype 12-1 and atherosclerosis progression and graft occlusion were only slightly attenuated (P ¼ 0.053 and P ¼ 0.023, respectively). Inclusion of DBP as a covariate in the association analysis of haplotype 12-4 with HDL-C response did not alter the significance of that result (P ¼ 0.009).
Discussion
In the Post-CABG cohort, we observed that haplotypes in the 3 0 -end of LPL were associated with progression/occlusion of atherosclerosis in coronary grafts as well as lipid response in patients receiving lovastatin therapy. LPL hydrolyzes TGs present in very low-density lipoprotein (VLDL) and chylomicron particles, releasing free fatty acids and monoacylglycerol. 16 LPL activity also indirectly raises HDL-C levels because LPL-mediated hydrolysis of VLDL-TG provides surface components that merge with HDL3 to form HDL2 particles. 17 Therefore, it is not surprising that TG and HDL-C response, but not LDL-C response, to statin therapy appears to be influenced by genetic variation in LPL. Of note, we adjusted for lovastatin treatment group (moderate or aggressive lipid lowering) in our association analyses, and thus can conclude that the effect of LPL haplotypes on lipid response was independent of the statin dose. Effects of haplotypes 12-1 and 12-4 on atherosclerosis progression and HDL-C response, respectively, were also independent of haplotype effects on DBP.
Although genetic variation in LPL may influence lipid response to statin therapy simply by modulating lipid metabolism, another possible mechanism is that statins affect LPL expression and/or activity. In the latter model, genetic variation in LPL could alter the effect of statins on LPL expression. A number of investigators have hypothesized that the effect of statins on TG and HDL-C may be mediated via an effect on LPL. Rodent studies have produced conflicting results, showing either increased post-heparin LPL activity in rats treated with simvastatin, 18 or no effects on LPL activity in rats treated with lovastatin 19 or guinea-pigs treated with pitavastatin. 20 An in vitro cellular study utilizing 3T3L1 adipocytes showed a dose-and timedependent increase in LPL mRNA levels in response to administration of atorvastatin. 21 Administration of the potent statins simvastatin or atorvastatin to humans with hyperlipidemia and/or diabetes led to increases in preheparin LPL mass or post-heparin LPL activity in three out of four studies. [22] [23] [24] [25] The weaker statin fluvastatin did not alter LPL activity in dyslipidemic subjects. 26 Given this evidence of statin modulation of LPL activity, the LPL haplotypes we analyzed may affect lipid response to statin by altering the responsiveness of LPL expression or activity to statins.
The LPL haplotype association results in this study are concordant with our prior studies of LPL haplotypes in Mexican Americans at risk for coronary artery disease, the Mexican-American Coronary Artery Disease (MACAD) study. 8, 11, 12 In this study, haplotype 12-1 was associated with protection against graft worsening or occlusion. Haplotype 12-1 is equivalent to haplotype 19-1, which was associated with a lower prevalence of coronary artery disease in Mexican Americans. 11 That this haplotype was not associated with lipids at baseline or in response to statin therapy suggests that the effect on atherosclerosis may be independent of LPL's effect in modulating lipid levels. Indeed, LPL may affect atherosclerosis risk by mechanisms independent of circulating cholesterol and TG levels. LPL has been shown to stimulate vascular smooth muscle cell proliferation in vitro. 27 Yet another atherogenic effect of LPL is its ability to promote monocyte adhesion to bovine aortic endothelial cells. 28 Perhaps these effects are less prominent in those individuals with haplotype 12-1.
On the other hand, our prior work suggested that haplotype 12-4 may be deleterious in terms of metabolic and cardiovascular risk. 8, 11, 12 Possibly consistent with haplotype 12-4 as a risk haplotype, the current study demonstrated an association of haplotype 12-4 with a reduced HDL-C increase in response to statin therapy. In our MACAD study, this haplotype was associated with a trend to increased coronary artery disease prevalence as well as insulin resistance, elevated body mass index, elevated SBP, elevated HDL-C and elevated post-heparin LPL activity. 8, 11, 12 The findings of increased baseline HDL-C and elevated DBP with haplotype 12-4 in this study are concordant with our prior findings of elevated HDL-C and SBP in Mexican Americans. 12 Elevated HDL-C in carriers of this haplotype is consistent with increased LPL activity. The harmful effects in terms of insulin sensitivity, body mass index and blood pressure are likely related to local effects of LPL in mediating lipid uptake in muscle, adipose and the vascular wall, respectively. 29 In terms of the attenuation of HDL-C increase in response to statin observed in this study, a plausible hypothesis is that carriers of haplotype 12-4 have relatively elevated LPL activity at baseline such that, when taking a statin, these subjects experience a lesser increase in LPL activity and thus experience a lower HDL-C increment. Perhaps the elevated baseline HDL-C explains why haplotype 12-4 was not significantly associated with graft worsening, despite the lower HDL-C increment on statin therapy. Alternatively, the low frequency of this haplotype may have reduced our ability to detect its association with graft progression. In any case, the clinical relevance to atherosclerosis of the haplotype 12-4 effect on HDL-C is uncertain, given that this haplotype was not significantly associated with graft worsening. Also, the modest effect of statins on HDL-C is not considered to be a major mechanism whereby these agents lower cardiovascular risk.
In the Post-CABG trial, on average TG levels increased by 7.5%, likely a reflection of the weak effect of lovastatin on TGs. 15 Haplotype 12-2 carriers experienced a smaller increase in TG level. Whether this is a true pharmacogenetic effect could be tested in a trial utilizing a statin expected to lower TGs (e.g. atorvastatin) or a trial of an agent specifically targeting TGs (e.g. a fibrate).
Because the enzymatic action of LPL is most directly on TGs, it was unexpected that the most dramatic pharmacogenetic effects were on HDL-C response. The Post-CABG trial is atypical compared to other statin trials in the relatively large mean HDL-C response (Table 1) . Perhaps this large response allowed us to detect the modulating effects of the LPL haplotypes. Although the pharmacogenetic effects of LPL on HDL-C and TG response are of unknown clinical significance, this study does provide mechanistic insight into the possible role of LPL in lipid response to statin therapy. This study supports the concept that common genetic variation in the LPL locus influences the HDL/TG axis in dynamic states (e.g. during treatment).
There have been very few studies examining the pharmacogenetic effects of LPL variation on the response to statin treatment. The REGRESS trial, a study of 819 subjects treated with pravastatin or placebo for 2 years, found that the D9N variant was associated with increased risk of coronary artery disease progression and clinical events in the placebo group. Atherosclerosis was not affected by the presence of this variant in the pravastatin group, suggesting that pravastatin overcame the harmful effects of the D9N variant. 13 On the other hand, D9N carriers experienced an attenuated TC and LDL-C response to pravastatin treatment in the REGRESS trial. D9N was not considered in the current study because of our previous demonstration of its lack of effect on graft progression in the Post-CABG cohort 14 and its location upstream of a recombination hotspot in intron 6 of LPL, 30 which separates it from the 3 0 -end haplotypes we have been studying.
Our initial pharmacogenetic study in the Post-CABG cohort showed that the HindIII variant (and a closely linked tetranucleotide repeat) was associated with increased risk of graft progression; homozygotes for the minor allele of HindIII had increased risk.
14 Haplotype 12-4 carries the minor (risk) allele of HindIII. Haplotype 12-1, herein associated with protection against graft progression, carries the major allele at HindIII. HindIII was not associated with HDL-C response to statin therapy. The present results explain why this was the case. The rare allele of HindIII is present on both haplotype 12-4 (associated with decreased HDL-C response) and haplotype 12-6 (associated with increased HDL-C response). When considering only the HindIII variant, subjects with these haplotypes are indistinguishable and the lipid responses averaged together, resulting in no effect of HindIII on HDL-C response to statin therapy.
Cladistic analysis of the LPL gene has shown that the haplotype structure of the 3 0 -end of the gene is ancient and should be reflected in similar haplotypes across different population groups. 31 Consistent with this prediction, our studies of the haplotype structure of the 3 0 -end of LPL in Mexican Americans and now two independent Caucasian samples have found the same common haplotypes in each of the populations studied. 11 As haplotype 12-4 (equivalent to the prior 19-4) appears to be associated with adverse atherosclerotic or metabolic risk in different populations, it is likely that an ancient variant arose on this common haplotype background that was then dispersed across different populations. Most likely this variant was beneficial in the era of scarce food and high physical activity, consistent with the thrifty genotype hypothesis, 32 but is harmful in the modern era of excess food and low physical activity.
We note that HDL-C response to statin therapy was quite variable, as evidenced by the large standard deviation in HDL-C response. Similar high standard deviations were observed when examining the moderate and aggressive treatment groups separately. We hypothesize that genetic factors, such as variation in the LPL gene and likely additional genes, are responsible in part for this wide variability in HDL-C response. To our knowledge, no study has examined the heritability of lipid response to statin treatment. Such would require study in families. The alternative approach, successfully applied here, is to study specific candidate genes, such as the recent report of the influence of HMG-CoA reductase gene variation on LDL-C response to statin therapy. 33 Multiple testing is an issue that applies to all genetic studies in which multiple genetic variants are tested for association against multiple traits. In such studies, including ours, adjusting for multiple comparisons by such methods as Bonferroni corrections that assume all the tests are independent are often not utilized because they result in a significance level that is too stringent owing to the fact that the SNPs in the same gene are correlated, as are the phenotypes. In an effort to minimize multiple testing, we restricted our analyses to haplotype associations rather than associations of the 12 individual SNPs. Moreover, in this study, we were specifically interested in extending the haplotype association results of the LPL haplotypes (19-1 and 19-4) found associated with insulin resistance and atherosclerosis in our prior studies. 8, 11 That we found associations of the equivalent haplotypes 12-1 and 12-4 with graft progression and HDL-C response adds confidence to the association results reported herein.
In conclusion, this study demonstrates that haplotypes in the 3 0 -end of LPL, previously shown to modulate atherosclerosis, insulin resistance, blood pressure, obesity and static lipid levels, also influence atherosclerosis progression and HDL-C and TG response to statin treatment. The most common haplotype appears to be protective, whereas the fourth most common haplotype appears to confer increased risk. By influencing each of the factors of the metabolic syndrome, the LPL gene and its product emerge as important factors in the development and progression of atherosclerosis.
Materials and methods

Subjects
This genetic association study is ancillary to the PostCoronary Artery Bypass Graft Trial (Post-CABG Trial). 14, 15 A total of 1351 subjects from seven clinical centers throughout North America were included in the clinical trial and all were eligible as participants in this genetic ancillary study. Inclusion and exclusion criteria have been described previously. 15 Subjects were randomly assigned for treatment to lower LDL-C levels with lovastatin, aggressively (target LDL 1.55-2.20 mmol/l (60-85 mg/dl)), cholestryramine added to lovastatin if necessary to reach target) or moderately (target LDL 3.36-3.62 mmol/l (130-140 mg/dl)). For the genetic study, DNA was isolated from 903 subjects following standard protocols. 34 Follow-up complete angiographic data, lipid values and DNA were available from 891 of these individuals. See Figure 1 for a flowchart of subjects. Subjects in this genetic study were collected in the latter years of the larger Post-CABG trial. Our previous comparison of the genetic study subjects with the subjects not included in the genetic study found fewer cardiovascular events, greater aspirin use and more favorable lipid levels in the former, suggesting that subjects with lesser risk for atherosclerosis progression were disproportionately included in the genetic study. 14 
Genotyping and haplotype determination
In this study, 12 SNPs were genotyped for haplotype reconstruction. In this Post-CABG cohort, we previously genotyped the HindIII polymorphism located in intron 8 (rs320, also known as 8393 8, 11, 35 ) using conventional agarose gel techniques as described previously.
14 Subsequently, we designed PCR primers and TaqMan MGB (Applied Biosystems, Foster City, CA, USA) probes to genotype 11 additional LPL SNPs. These were selected based on our prior work demonstrating that haplotypes spanning exon 9 to exon 10 were associated with variation in postheparin plasma LPL activity and multiple phenotypes related to the metabolic syndrome in the Mexican-American Coronary Artery Disease (MACAD) cohort. 12 In our study of LPL in the MACAD cohort, we genotyped 19 SNPs; herein, we genotyped HindIII plus a subset of 11 essential SNPs. These 11 SNPs (rs328 (Ser447Stop, also known as 9040), rs11570892, rs3289, rs1803924, rs1059507, rs3735964, rs3200218, rs1059611, rs10645926, rs15285, rs3866471) either tag the common haplotypes in this region or are unique to a particular haplotype (termed 19-4) that was associated with increased LPL activity. 12 These 11 LPL SNPs were genotyped in 903 subjects using the 5 0 -exonuclease assay (TaqMan MGB) described previously.
11,36 PCR primers and TaqMan MGB probes for these 11 SNPs were reported previously. 11, 12 Haploview 3 was used to determine the haplotypes present in the study population. 37 Haploview constructs haplotypes by using an accelerated expectation maximization algorithm similar to the partition/ligation method, 38 which creates highly accurate population frequency estimates of the phased haplotypes based on the maximum likelihood derived from the unphased input genotypes. Haploview also identified six SNPs (rs328, rs3289, rs3735964, rs3200218, rs15285, rs3866471) that tag the haplotypes with frequency 40.01.
Of the 891 subjects genotyped at all 12 LPL variants, 829 with complete follow-up phenotypic data were assigned a haplogenotype using an in-house algorithm. This algorithm examined the genotype at all six haplotype tagging SNPs for each predicted possible combination of two haplotypes (i.e. haplogenotype); the genotypes at each tag SNP (1 ¼ homozygous for major allele; B ¼ heterozygous; 2 ¼ homozygous for minor allele) were considered together as a genotype pattern that is specific to a particular haplogenotype. In these data, each possible pair of haplotypes was reflected in a unique genotype pattern, with the exception of haplogenotype 12-1/12-4 and haplogenotype 12-6/12-8, both of which had the same genotype pattern (B1B1B1). The frequencies of these haplotypes (12-1: 0.431; 12-4: 0.057; 12-6: 0.035; 12-8: 0.022; Table 3 ) allowed a determination of the relative frequency of haplogenotype 12-1/12-4 versus 12-6/12-8 ((0.431 Â 0.057)/(0.035 Â 0.022) ¼ 32). Thus, haplogenotype 12-1/12-4 should be 32 times more common in the data than 12-6/12-8. In our population, 45 subjects had the ambiguous genotype pattern; assigning all of them a haplogenotype of 12-1/12-4 may have resulted in an error in B1 subject. This gives an overall error rate of 1/829 (0.12%).
Phenotyping
All demographic, family history, medical history and clinical data were collected as part of the Post-CABG Trial. 14 The progression of atherosclerosis was quantitatively determined by comparison of an initial angiogram at enrollment with a follow-up angiogram repeated an average of 4.3 years later. 15 Baseline and follow-up angiography were obtained with catheterization techniques that permitted computerassisted quantitative measurement. An initially patent graft was defined as having progression of atherosclerosis if there was a decrease of 0.6 mm or more in lumen diameter at the site of greatest change at follow-up. Subjects with 'progression of atherosclerosis' were defined as those subjects with one or more grafts showing progression. Graft occlusion was also assessed. Baseline and post-treatment lipid levels (TC, LDL-C, HDL-C and TGs) were obtained.
All procedures were approved by the institutional review boards of Cedars-Sinai Medical Center and the other centers participating in the Post-CABG Trial. Informed consent for the clinical trial was obtained before enrollment and consent for this genetic study was obtained during followup.
Association analysis
The primary phenotypes analyzed for association with LPL haplotypes were (a) the progression of atherosclerosis and (b) lipid response to lovastatin therapy. Secondary analyses included association of the LPL haplotypes with baseline lipid and SBP and DBP measurements.
Association of LPL haplotypes with presence/absence of atherosclerosis progression and with presence/absence of graft occlusion was evaluated using logistic regression. Association with TC, LDL-C, HDL-C and TG response to lovastatin therapy, baseline lipid and baseline blood pressure measurements was evaluated using analysis of covariance (ANCOVA). All analyses were adjusted for age, gender, current smoking status, time between CABG and enrollment, race and lovastatin group (moderate or aggressive) by inclusion of these parameters as independent variables in the logistic regression or ANCOVA analyses. Quantitative trait values were log-transformed as appropriate to reduce non-normality. For each haplotype analysis, haplogenotype was coded as an independent variable as 'carrier' or 'noncarrier.' Single SNP association analyses were not carried out, both to reduce the number of statistical tests and because our interest is in association of LPL haplotypes with atherosclerotic and metabolic phenotypes. 
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